Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy
- 2 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 28 (11), 5569-5579
- https://doi.org/10.1007/s00520-020-05478-x
Abstract
Purpose The aim of this study was to evaluate the nutrition and metabolism status alteration during immunotherapy in advanced hepatocellular carcinoma (HCC) patients. Methods Patients with advanced HCC who participated in the clinical trials of single-agent anti-PD-1 immunotherapy or sorafenib were retrospectively included. We analyzed self-comparison of the nutritional and metabolic indices of patients in the anti-PD-1 and sorafenib treatment group. We conducted mutual-comparison of the mentioned indices between the disease progression group and disease control group among anti-PD-1 treatment patients. We further analyzed those indices with statistical differences by partial correlation and survival analysis. Results Both self-comparison before and after treatment in the anti-PD-1 group and mutual-comparison of disease progression and the control group showed significant differences in multiple indices, but we did not observe significant differences in the sorafenib group. Strikingly, albumin (ALB)/prognostic nutritional index (PNI, calculated by serum albumin and lymphocyte count) decreased distinctly in the immunotherapy disease progression group patients. However, changes in ALB/PNI were not significant in disease progression patients from the sorafenib group or in the disease control patients with immunotherapy. Partial correlation analysis suggested that ALB and PNI were positively correlated with the efficacy of immunotherapy. Furthermore, survival analysis showed that the median progression-free survival and median overall survival of patients in the ALB/PNI decreased group were significantly shorter than those of patients from the ALB/PNI increased group. Conclusion Anti-PD-1 immunotherapy might alter the nutritional and metabolic status in advanced HCC patients. We also should pay attention to the nutritional and metabolic status of patients when drug resistance is detected.Funding Information
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China (81802350)
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China (81802355)
- National Major Science and Technology Projects of China (2017ZX10203205)
- Zhejiang provincial medical and health young talents project of China (2019RC285)
This publication has 51 references indexed in Scilit:
- The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancerEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2013
- Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatmentBiomedicine & Pharmacotherapy, 2013
- Metabolic Regulation of T LymphocytesAnnual Review of Immunology, 2013
- Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in CancerCell Metabolism, 2012
- Cancer Cachexia: Mediators, Signaling, and Metabolic PathwaysCell Metabolism, 2012
- A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)British Journal of Cancer, 2012
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- The metabolic life and times of a T‐cellImmunological Reviews, 2010
- Enhancing CD8 T-cell memory by modulating fatty acid metabolismNature, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008